# High-intensity Statin and Ezetimibe Therapy for Asymptomatic Patients With Positive Coronary Calcium

Study · id `cardio:ct-nct05845424` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05845424](<https://clinicaltrials.gov/study/NCT05845424>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05845424

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 6000 participants.

## Technical summary

Registry record NCT05845424. Randomized; no masking; primary purpose treatment. Start 2023-07-03 (actual); primary completion 2029-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 6000 participants (planned count; ClinicalTrials.gov record NCT05845424, source copy `cardio:ctgov-nct05845424-2025-01-14`, retrieved 2026-10-31)
- Started: 2023-07-03 (actual) (ClinicalTrials.gov record NCT05845424, source copy `cardio:ctgov-nct05845424-2025-01-14`, retrieved 2026-10-31)
- Primary completion: 2029-06-30 (anticipated) (ClinicalTrials.gov record NCT05845424, source copy `cardio:ctgov-nct05845424-2025-01-14`, retrieved 2026-10-31)
- Completion: 2030-06-30 (anticipated) (ClinicalTrials.gov record NCT05845424, source copy `cardio:ctgov-nct05845424-2025-01-14`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT05845424, source copy `cardio:ctgov-nct05845424-2025-01-14`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05845424-2025-01-14`, retrieved 2026-10-31)

## The registry's words

- Brief title: High-intensity Statin and Ezetimibe Therapy for Asymptomatic Patients With Positive Coronary Calcium
- Acronym: DECISION-CAL
- Condition: Coronary Artery Calcification
- Condition: Metabolic Syndrome
- Condition: Dyslipidemias
- Intervention (Drug): Guideline directed statin therapy
- Intervention (Drug): High intensity statin plus ezetimibe therapy
- Lead sponsor: Samsung Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Metabolic syndrome (`cardio:metabolic-syndrome`)
- Registry lists this organization as the lead sponsor: Samsung Medical Center (`cardio:org-samsung-medical-center`)

## Provenance

Content hash: a21e901397f41f60d13f44c6bdfd1716f431710e041591e7e82016cfa90800bb
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
